Exploration of Targeted Anti-tumor Therapy

Table 2. Table showing the gene fusions and exon skipping called by ADx in samples investigated by lung panel

Samples	Histology/Diagnosis*	Lung panel ADx	FISH
32	Aggressive glial neoplasia^a	KIF5C-ALK	ALK confirmed
33	Poorly differentiated lung adenocarcinoma	EML4-ALK	ALK confirmed
34	Lung adenocarcinoma^a	KIF5B-RET	RET confirmed^b
35	Thyroid papillary carcinoma	RET-NCOA4	RET confirmed
36	Thyroid papillary carcinoma	RELCH-RET	RET confirmed
37	NTRK-rearranged spindle cell sarcoma	TPM3-NTRK1	NTRK1 confirmed^b
38	Liver adenocarcinoma^a	FGFR2-TACC3	FGFR2 non canonical
39	Secretory carcinoma of the parotid	ETV6-NTRK3	ETV6-NTRK3 confirmed
40	Non small cell carcinoma with sarcomatoid features	TPM3-NTRK1	NTRK1 not confirmed
41	Pilocytic astrocitoma^a	KIAA1549-BRAF	Not done
42	Intracranic astrocitoma^a	KIAA1549-BRAF	Not done
43	Lung adenocarcinoma	EML4-ALK	Not done
44	Thyroid papillary carcinoma^a	TPR-NTRK1	Not done
45	Lung adenocarcinoma	EML4-ALK	Not done
46	Lung adenocarcinoma	EML4-ALK	Not done
47	NTRK rearranged inflammatory myofibroblastic tumor	ETV6-NTRK3	Not done
48	NTRK rearranged Spindle cell Sarcoma	TPM3-NTRK1	Not done
49	NTRK rearranged Spindle cell Sarcoma	TPM3-NTRK1	Not done
50	NTRK rearranged Spindle cell Sarcoma	TPR-NTRK1	Not done
51	Parotid carcinoma^a	ETV6-NTRK3	Not done
52	NTRK rearranged spindle cell neoplasm	TFG-NTRK3	Not done
53	Talamic neoformation	NTRK2 exon5 skipping	Not achievable
54	Embryonal rhabdomyosarcoma	NTRK2 exon 5 skipping	Not achievable
55	Cerebellar HGNET-BCOR mutated^a	NTRK3 exons 13–15 skipping	Not achievable
56	Frontal expansive lesion^a	NTRK3 exon 16 skipping	Not achievable
57	Lung adenocarcinoma	MET exon 14 skipping	Not achievable
58	Lung adenocarcinoma	MET exon 14 skipping	Not achievable
59	Lung adenocarcinoma	MET exon 14 skipping	Not achievable
60	Neuroendocrine tumor (atypical carcinoid)	RET exons 4–7 skipping	Not achievable

Return to article view

a: external diagnosis. b: RNAseq was performed on surgical samples while FISH was done on CNBs prior surgery. *: According to WHO classification of Soft tissue and bone tumors [17] and to WHO classification of Thoracic tumors [22]; KIF5C: kinesin family member 5C; EML4: EMAP like 4; RELCH: RAB11 binding and LisH domain, coiled-coil and HEAT repeat containing; TPM3: tropomyosin 3; TACC3: transforming acidic coiled-coil containing protein 3; TPR: translocated promoter region, nuclear basket protein

Supplementary materials

The supplementary materials for this article are available at: https://www.explorationpub.com/uploads/Article/file/1002102_sup_1.pdf.

Declarations

Author contributions

FB: Writing – original draft; IC, EC, AB, GD, MAT, VM, MD, CP, SD, AV, PC, and DL: Investigation; LA, PV, and AD: Software and Formal analysis; AP, IC, FB: Data curation; IC, FB, GD, FP, ET, PC, DL, AV, LA, and GP: Writing – review & editing. GP: Supervision. All the authors read and approved the submitted version.

Conflicts of interest

The authors declare that they have no conflicts of interest.

Ethical approval

This study was performed according with the Declaration of Helsinki and approved by the Ethics committee of Fondazione IRCCS Istituto Nazionale Tumori Milano (INT 277/20).

Consent to participate

Written informed consent to participate in the study was obtained from all participants.

Consent to publication

Not applicable.

Availability of data and materials

The raw data supporting the conclusions of this manuscript will be made available by the authors (luca.agnelli@istitutotumori.mi.it), without undue reservation, to any qualified researcher.

Funding

Not applicable.

Copyright

References

Kumar-Sinha C, Kalyana-Sundaram S, Chinnaiyan AM. Landscape of gene fusions in epithelial cancers: seq and ye shall find. Genome Med. 2015;7:129. [DOI] [PubMed] [PMC]

Kozuma Y, Toyokawa G, Seto T. ALK testing methods: is there a winner or loser? Expert Rev Anticancer Ther. 2019;19:237–44. [DOI] [PubMed]

Marchiò C, Scaltriti M, Ladanyi M, Iafrate AJ, Bibeau F, Dietel M, et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. Ann Oncol. 2019;30:1417–27. [DOI] [PubMed]

Rossi G, Ragazzi M, Tamagnini I, Mengoli MC, Vincenzi G, Barbieri F, et al. Does immunohistochemistry represent a robust alternative technique in determining drugable predictive gene alterations in non-small cell lung cancer? Curr Drug Targets. 2017;18:13–26. [DOI] [PubMed]

List of cleared or approved companion diagnostic devices (in vitro and imaging tools) [Internet]. U.S. Food & Drug Administration; c2022 [cited 2022 Aug 1]. Available from: https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools

Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31:1491–505. [DOI] [PubMed]

Pruneri G, De Braud F, Sapino A, Aglietta M, Vecchione A, Giusti R, et al. Next-generation sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach? Pharmacoecon Open. 2021;5:285–98. [DOI] [PubMed] [PMC]

Ramani NS, Patel KP, Routbort MJ, Alvarez H, Broaddus R, Chen H, et al. Factors impacting clinically relevant RNA fusion assays using next-generation sequencing. Arch Pathol Lab Med. 2021;145:1405–12. [DOI] [PubMed]

Uhrig S, Ellermann J, Walther T, Burkhardt P, Fröhlich M, Hutter B, et al. Accurate and efficient detection of gene fusions from RNA sequencing data. Genome Res. 2021;31:448–60. [DOI] [PubMed] [PMC]

10.

Haas BJ, Dobin A, Stransky N, Li B, Yang X, Tickle T, et al. STAR-fusion: fast and accurate fusion transcript detection from RNA-Seq. BioRxiv. 2017;[Epub ahead of print]. [DOI]

11.

Haas BJ, Dobin A, Li B, Stransky N, Pochet N, Regev A. Accuracy assessment of fusion transcript detection via read-mapping and de novo fusion transcript assembly-based methods. Genome Biol. 2019;20:213. [DOI] [PubMed] [PMC]

12.

Racanelli D, Brenca M, Baldazzi D, Goeman F, Casini B, De Angelis B, et al. Next-generation sequencing approaches for the identification of pathognomonic fusion transcripts in sarcomas: the experience of the Italian ACC sarcoma working group. Front Oncol. 2020;10:489. [DOI] [PubMed] [PMC]

13.

Argani P, Lewin JR, Edmonds P, Netto GJ, Prieto-Granada C, Zhang L, et al. Primary renal sclerosing epithelioid fibrosarcoma: report of 2 cases with EWSR1-CREB3L1 gene fusion. Am J Surg Pathol. 2015;39:365–73. [DOI] [PubMed] [PMC]

14.

Brassesco MS, Cortez MA, Valera ET, Engel EE, Nogueira-Barbosa MH, Becker AP, et al. Cryptic SYT/SXX1 fusion gene in high-grade biphasic synovial sarcoma with unique complex rearrangement and extensive BCL2 overexpression. Cancer Genet Cytogenet. 2010;196:189–93. [DOI] [PubMed]

15.

Torres L, Lisboa S, Cerveira N, Lopes JM, Lopes C, Teixeira MR. Cryptic chromosome rearrangement resulting in SYT-SSX2 fusion gene in a monophasic synovial sarcoma. Cancer Genet Cytogenet. 2008;187:45–9. [DOI] [PubMed]

16.

Yoshida A, Arai Y, Kobayashi E, Yonemori K, Ogura K, Hama N, et al. CIC break-apart fluorescence in-situ hybridization misses a subset of CIC-DUX4 sarcomas: a clinicopathological and molecular study. Histopathology. 2017;71:461–9. [DOI] [PubMed]

17.

Soft tissue and bone tumours–WHO classification of tumours, 5th edition, volume 3 [Internet]. Lyon: International agency for research on Cancer (IARC); c2022 [cited 2022 Aug 1]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Soft-Tissue-And-Bone-Tumours-2020

18.

Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res. 2012;18:4570–9. [DOI] [PubMed] [PMC]

19.

Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, et al. Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer. 2013;119:1627–35. [DOI] [PubMed]

20.

Dickson BC, Antonescu CR, Argyris PP, Bilodeau EA, Bullock MJ, Freedman PD, et al. Ectomesenchymal chondromyxoid tumor: a neoplasm characterized by recurrent RREB1-MKL2 fusions. Am J Surg Pathol. 2018;42:1297–305. [DOI] [PubMed] [PMC]

21.

Siegfried A, Romary C, Escudié F, Nicaise Y, Grand D, Rochaix P, et al. RREB1-MKL2 fusion in biphenotypic “oropharyngeal” sarcoma: new entity or part of the spectrum of biphenotypic sinonasal sarcomas? Genes Chromosomes Cancer. 2018;57:203–10. [DOI] [PubMed]

22.

Thoracic tumours–WHO classification of tumours, 5th edition, volume 5 [Internet]. Lyon: International agency for research on Cancer (IARC); c2022 [cited 2022 Aug 1]. Available from: https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-Tumours/Thoracic-Tumours-2021

23.

Maraka S, Janku F. BRAF alterations in primary brain tumors. Discov Med. 2018;26:51–60. [PubMed]

24.

Liu M, Chen P, Hu HY, Ou-Yang DJ, Khushbu RA, Tan HL, et al. Kinase gene fusions: roles and therapeutic value in progressive and refractory papillary thyroid cancer. J Cancer Res Clin Oncol. 2021;147:323–37. [DOI] [PubMed]

25.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6. [DOI] [PubMed]

26.

Demetri GD, Antonescu CR, Bjerkehagen B, Bovée JVMG, Boye K, Chacón M, et al. Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network. Ann Oncol. 2020;31:1506–17. [DOI] [PubMed] [PMC]

27.

Bubendorf L, Büttner R, Al-Dayel F, Dietel M, Elmberger G, Kerr K, et al. Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch. 2016;469:489–503. [DOI] [PubMed] [PMC]

28.

Lee SE, Lee B, Hong M, Song JY, Jung K, Lira ME, et al. Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Mod Pathol. 2015;28:468–79. [DOI] [PubMed]

29.

Thompson ER, Lim KJC, Kuzich JA, McBean M, Westerman D, Tam CS, et al. Detection of an IGH-BRAF fusion in a patient with BRAF Val600Glu negative hairy cell leukemia. Leuk Lymphoma. 2020;61:2024–6. [DOI] [PubMed]

30.

Kannan S, Lock I, Ozenberger BB, Jones KB. Genetic drivers and cells of origin in sarcomagenesis. J Pathol. 2021;254:474–93. [DOI] [PubMed]

31.

Le Loarer F, Cleven AHG, Bouvier C, Castex MP, Romagosa C, Moreau A, et al. A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Mod Pathol. 2020;33:404–19. [DOI] [PubMed]

32.

Xu B, Suurmeijer AJH, Agaram NP, Zhang L, Antonescu CR. Head and neck rhabdomyosarcoma with TFCP2 fusions and ALK overexpression: a clinicopathological and molecular analysis of 11 cases. Histopathology. 2021;79:347–57. [DOI] [PubMed] [PMC]

33.

Fukuhara S, Nomoto J, Kim SW, Taniguchi H, Miyagi Maeshima A, Tobinai K, et al. Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma. Hematol Oncol. 2018;36:150–8. [DOI] [PubMed]

34.

Haas BJ, Zody MC. Advancing RNA-Seq analysis. Nat Biotechnol. 2010;28:421–3. [DOI] [PubMed]

35.

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. [DOI] [PubMed] [PMC]

36.

Heydt C, Wölwer CB, Velazquez Camacho O, Wagener-Ryczek S, Pappesch R, Siemanowski J, et al. Detection of gene fusions using targeted next-generation sequencing: a comparative evaluation. BMC Med Genomics. 2021;14:62. [DOI] [PubMed] [PMC]

37.

Davies KD, Le AT, Sheren J, Nijmeh H, Gowan K, Jones KL, et al. Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples. J Thorac Oncol. 2018;13:1474–82. [DOI] [PubMed] [PMC]

38.

Kuang Y, Xu P, Wang J, Zheng Y, Sun X, Li Z, et al. Detecting ALK rearrangement with RT-PCR: a reliable approach compared with next-generation sequencing in patients with NSCLC. Mol Diagn Ther. 2021;25:487–94. [DOI] [PubMed] [PMC]